Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)

CAPS Rating: 2 out of 5

The Company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other unmet medical needs.


Player Avatar zzlangerhans (99.80) Submitted: 7/5/2013 12:39:34 PM : Underperform Start Price: $5.56 SNSS Score: +11.56

Sunesis seems to have settled into a tight trading range since March, and I see 5.5 as a good trigger to set an underperform so as to take maximal advantage of the fluctuations. I'll likely stick with red thumbs because I think the stock is massively overvalued considering the negative implications of the 2012 interim analysis, which I delineated in one of my previous underperform pitches. As of now, topline data from the VALOR trial is expected in H1 2014 and I'm hoping for a huge upward run that will make puts enormously profitable.

Featured Broker Partners